-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose? - Live Q&A

Program: Education Program
Monday, December 7, 2020: 9:00 AM-9:45 AM

Description:
The genomic revolution has transformed our understanding of the pathophysiology of the myeloproliferative neoplasms (MPN), and has redefined MPN diagnostic criteria. The myeloproliferative neoplasms are indolent diseases where survival is measured in decades, yet morbidity and mortality vary widely. In addition to transforming diagnostic criteria, genomics have informed nearly every aspect of MPN. This educational session will explore the evidence for comprehensive genomic assessment during stages of MPN from initial evaluation, through evolution and transformation.

Dr. Alison Moliterno will outline the evidence for use of genomic testing in evaluating MPN presentation across varied clinical contexts. She will discuss the evidence supporting the use of clonal genomic burden in determining MPN subtypes and assessing thrombosis risk, and its use in clinical decision making.

Dr. Olatoyosi Odenike will discuss how genomics informs the evaluation and management of MPN progression. The therapies for MPN have expanded, and the genomics of clonal progression and transformation can be a guiding light in assessing suitability for therapies to meet treatment goals.

Dr. Mrinal Patnaik will discuss the opportunities and challenges that genomics offers in the management of myeloproliferative/myelodysplastic syndromes. He will discuss the insights that genomics has produced in illuminating these complex syndromes, and will highlight how genomic assessment will light the way to targeted therapy.

Chair:
Alison R. Moliterno, MD, Johns Hopkins University School of Medicine
Disclosures:
Moliterno: MPNRF: Research Funding; Pharmessentia: Consultancy.
Panelists:
Mrinal M. Patnaik, MD, MBBS, MAYO , Alison R. Moliterno, MD, Johns Hopkins University School of Medicine and Olatoyosi Odenike, MD, University of Chicago
Disclosures:
Moliterno: MPNRF: Research Funding; Pharmessentia: Consultancy. Odenike: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Impact Biomedicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Other: Institutional research funding; Astra Zeneca: Research Funding; Astex Pharmaceuticals, NS Pharma, Gilead Sciences, Janssen Oncology, Oncotherapy, Agios, CTI/Baxalta, Aprea: Other: Institutional research funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees.
The genomic revolution has transformed our understanding of the pathophysiology of the myeloproliferative neoplasms (MPN), and has redefined MPN diagnostic criteria. The myeloproliferative neoplasms are indolent diseases where survival is measured in decades, yet morbidity and mortality vary widely. In addition to transforming diagnostic criteria, genomics have informed nearly every aspect of MPN. This educational session will explore the evidence for comprehensive genomic assessment during stages of MPN from initial evaluation, through evolution and transformation.

Dr. Alison Moliterno will outline the evidence for use of genomic testing in evaluating MPN presentation across varied clinical contexts. She will discuss the evidence supporting the use of clonal genomic burden in determining MPN subtypes and assessing thrombosis risk, and its use in clinical decision making.

Dr. Olatoyosi Odenike will discuss how genomics informs the evaluation and management of MPN progression. The therapies for MPN have expanded, and the genomics of clonal progression and transformation can be a guiding light in assessing suitability for therapies to meet treatment goals.

Dr. Mrinal Patnaik will discuss the opportunities and challenges that genomics offers in the management of myeloproliferative/myelodysplastic syndromes. He will discuss the insights that genomics has produced in illuminating these complex syndromes, and will highlight how genomic assessment will light the way to targeted therapy.

See more of: Education Program
<< Previous Session | Next Session >>